Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 4/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | MTAP | Q13126 | 13/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31237560 | 1.00 | PNP (0.58) | PNPHIF1AMTAP | |
| SCHEMBL11201279 | 0.85 | PNP (0.50) | PNPHIF1AMTAP | |
| SCHEMBL10858597 | 0.82 | PNP (0.53) | PNPHIF1A | |
| SCHEMBL11194201 | 0.82 | PNP (0.47) | PNPHIF1AMTAP | |
| Formycin SCHEMBL14074914 | 0.79 | HIF1A (0.61) | HIF1A | |
| Formycin SCHEMBL15262901 | 0.79 | HIF1A (0.61) | HIF1A | |
| Formycin SCHEMBL980049 | 0.79 | HIF1A (0.61) | HIF1A | |
| SCHEMBL3305081 | 0.78 | PNP (0.80) | PNP | |
| SCHEMBL3305072 | 0.78 | PNP (0.80) | PNP | |
| SCHEMBL3297704 | 0.76 | PNP (0.51) | PNPMTAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093991-A1 | METHODS FOR THE PREPARATION OF 9-DEAZAPURINE DERIVATIVES | BIO CRYST PHARMACEUTICALS , INC. (US) | 2010-04-15 | — | — | US | claimed |
| EP-0071227-A1 | Anti-leukemic beta-glycosyl C-nucleosides | Sloan-Kettering Institute For Cancer Research (US) | 1983-02-09 | — | — | EP | claimed |
| EP-4232456-A1 | ANTIVIRAL PRODRUG COMPOUNDS | Ligand Pharmaceuticals, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| WO-2022086958-A1 | ANTIVIRAL PRODRUG COMPOUNDS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2022-04-28 | — | — | WO | disclosed |
| US-8344132-B2 | Methods for the preparation of 9-deazapurine derivatives | BioCryst Pharmaceticals, Inc. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8344132-B2 | Methods for the preparation of 9-deazapurine derivatives | BioCryst Pharmaceticals, Inc. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20100093991-A1 | METHODS FOR THE PREPARATION OF 9-DEAZAPURINE DERIVATIVES | BIO CRYST PHARMACEUTICALS , INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100093991-A1 | METHODS FOR THE PREPARATION OF 9-DEAZAPURINE DERIVATIVES | BIO CRYST PHARMACEUTICALS , INC. (US) | 2010-04-15 | — | — | US | disclosed |
| WO-2007002191-A2 | METHODS FOR THE PREPARATION OF 9-DEAZAPURINE DERIVATIVES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-4584369-A | ANTICANCER AGENTS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1986-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093991-A1 | METHODS FOR THE PREPARATION OF 9-DEAZAPURINE DERIVATIVES | DPYD, TYMP, UNG | PNP 8/4885HIF1A 1572/4885MTAP 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.